In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 170 for your search:
Drug:  sorafenib tosylate
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: ONC-2010-19, NCT01203787

2.

Phase: Phase IV
Type: Natural history/Epidemiology
Status: Approved-not yet active
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15246, NX0913IN, NCT01353794

3.

Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 2011PTAHCC, NCT01409499

4.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: INT 80/09, NCT01387503

5.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11718, UVACC-ONYX-11718, UVACC-HIC-11860, EUDRACT-2005-0000941-12, BAYER-UVACC-ONYX-11718, NCT00111007

6.

Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: MRC-RE05-SORCE, MRC-RE05-SORCE, EUDRACT ID 2006-006079-19, EU-20734, NCT00492258, SORCE, ISRCTN38934710

7.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000564099, IPC-BAYPAN, INCA-RECF0426, IPC-2005-006, BAYPAN, NCT00541021

8.

Phase: Phase III
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12311, 2007-002604-17, NCT00625378

9.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1208, E1208, NCT01004978

10.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-80802, CALGB 80802, NCT01015833

11.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: CDR0000666232, FFCD-PRODIGE-11, FFCD-0803, EUDRACT-2009-015785-64, EU-21005, FFCD-PRODIGE 11 – 0803, NCT01075555

12.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AHCC06, NCT01135056

13.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: SILIUS Phase III trial, NCT01214343

14.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTKI258A2302, 2009-015459-25, NCT01223027

15.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12444, 2010-018501-10, NCT01234337

16.

Phase: Phase III
Type: Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: Esperanz-002, NCT01265810

17.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CRUK-TACE-2, TACE-2, 07130, UCL-07130, EU-21108, CRUK-HE3005, EUDRACT-2008-005073-36, CRUK-13136, ISRCTN-93375053, CTA-20363/0272/001, BAYER-CRUK-TACE-2, BIOCOM-UK-CRUK-TACE-2, NCT01324076

18.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: COG-AAML1031, AAML1031, NCT01371981

19.

Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: BOOST, EudraCT number 2009-013870-42, NCT01405573

20.

Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 80
Sponsor: Other
Protocol IDs: CROSS-J-RCC, UMIN000003040, NCT01481870

21.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P101103, NCT01482442

22.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TS-103, NCT01556490

23.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 16037 / AN 33/11, 2011-004396-36, NCT01613846

24.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0572, N0572, NCT00329719

25.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 0603, NCT00414388
1     
New Search